Clinical and economic benefit of G-CSF administration in the prevention of chemo-induced neutropenia

Research output: Contribution to journalArticle

Abstract

Chemotherapy-induced neutropenia (CIN) is a frequent complication in cancer patients receiving myelosuppressive chemotherapy, which can result in life-threatening infections requiring prolonged hospitalization and increasingly cost management. Furthermore, scheduled chemotherapy may be reduced or delayed as a result of CIN, which negatively affects prognosis. Granulocyte colony-stimulating factors (G-CSF) stimulate neutrophil production and maturation, and can therefore reduce the incidence and severity of neutropenia. A pegylated form of filgrastim, pegfilgrastim, has been developed, and various trials have shown that a single fixed dose (6 mg) per chemotherapy cycle is safe and effective in adult patients regardless of their body weight, thus making it a simple, effective, and well-tolerated option. This paper summarizes recent clinical data and analyses its place in the context of recent guidelines.

Original languageEnglish
Pages (from-to)1-18
Number of pages18
JournalTrends in Medicine
Volume8
Issue number1
Publication statusPublished - Jan 2008

Fingerprint

Granulocyte Colony-Stimulating Factor
Neutropenia
Economics
Drug Therapy
Hospitalization
Neutrophils
Body Weight
Guidelines
Costs and Cost Analysis
Incidence
Infection
Neoplasms

Keywords

  • Chemotherapy
  • Filgrastim
  • Neutropenia
  • Pegfilgrastim
  • Prevention

ASJC Scopus subject areas

  • Internal Medicine
  • Pharmacology (medical)

Cite this

Clinical and economic benefit of G-CSF administration in the prevention of chemo-induced neutropenia. / Lorusso, Vito.

In: Trends in Medicine, Vol. 8, No. 1, 01.2008, p. 1-18.

Research output: Contribution to journalArticle

@article{46c14b49fce04ab8bcd3a8e6648971a4,
title = "Clinical and economic benefit of G-CSF administration in the prevention of chemo-induced neutropenia",
abstract = "Chemotherapy-induced neutropenia (CIN) is a frequent complication in cancer patients receiving myelosuppressive chemotherapy, which can result in life-threatening infections requiring prolonged hospitalization and increasingly cost management. Furthermore, scheduled chemotherapy may be reduced or delayed as a result of CIN, which negatively affects prognosis. Granulocyte colony-stimulating factors (G-CSF) stimulate neutrophil production and maturation, and can therefore reduce the incidence and severity of neutropenia. A pegylated form of filgrastim, pegfilgrastim, has been developed, and various trials have shown that a single fixed dose (6 mg) per chemotherapy cycle is safe and effective in adult patients regardless of their body weight, thus making it a simple, effective, and well-tolerated option. This paper summarizes recent clinical data and analyses its place in the context of recent guidelines.",
keywords = "Chemotherapy, Filgrastim, Neutropenia, Pegfilgrastim, Prevention",
author = "Vito Lorusso",
year = "2008",
month = "1",
language = "English",
volume = "8",
pages = "1--18",
journal = "Trends in Medicine",
issn = "1594-2848",
publisher = "Pharma Project Group Edizioni Scientifiche (PPG)",
number = "1",

}

TY - JOUR

T1 - Clinical and economic benefit of G-CSF administration in the prevention of chemo-induced neutropenia

AU - Lorusso, Vito

PY - 2008/1

Y1 - 2008/1

N2 - Chemotherapy-induced neutropenia (CIN) is a frequent complication in cancer patients receiving myelosuppressive chemotherapy, which can result in life-threatening infections requiring prolonged hospitalization and increasingly cost management. Furthermore, scheduled chemotherapy may be reduced or delayed as a result of CIN, which negatively affects prognosis. Granulocyte colony-stimulating factors (G-CSF) stimulate neutrophil production and maturation, and can therefore reduce the incidence and severity of neutropenia. A pegylated form of filgrastim, pegfilgrastim, has been developed, and various trials have shown that a single fixed dose (6 mg) per chemotherapy cycle is safe and effective in adult patients regardless of their body weight, thus making it a simple, effective, and well-tolerated option. This paper summarizes recent clinical data and analyses its place in the context of recent guidelines.

AB - Chemotherapy-induced neutropenia (CIN) is a frequent complication in cancer patients receiving myelosuppressive chemotherapy, which can result in life-threatening infections requiring prolonged hospitalization and increasingly cost management. Furthermore, scheduled chemotherapy may be reduced or delayed as a result of CIN, which negatively affects prognosis. Granulocyte colony-stimulating factors (G-CSF) stimulate neutrophil production and maturation, and can therefore reduce the incidence and severity of neutropenia. A pegylated form of filgrastim, pegfilgrastim, has been developed, and various trials have shown that a single fixed dose (6 mg) per chemotherapy cycle is safe and effective in adult patients regardless of their body weight, thus making it a simple, effective, and well-tolerated option. This paper summarizes recent clinical data and analyses its place in the context of recent guidelines.

KW - Chemotherapy

KW - Filgrastim

KW - Neutropenia

KW - Pegfilgrastim

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=39649110876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39649110876&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:39649110876

VL - 8

SP - 1

EP - 18

JO - Trends in Medicine

JF - Trends in Medicine

SN - 1594-2848

IS - 1

ER -